20-F: Cuprina Holdings Files Annual Report on Form 20-F

Cuprina Holdings (Cayman) Limited has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025, detailing its financial performance, business operations, and future outlook.

Summary

• Cuprina Holdings (Cayman) Limited filed its annual report on Form 20-F for the fiscal year ended December 31, 2025.
• The company reported a net loss of S$4,673,447 (US$3,633,248) for the year, an increase from the previous year's net loss of S$1,560,535.
• Revenue for the year increased slightly to S$49,894 (US$38,789) from S$48,321 in the prior year, primarily driven by sales of its MEDIFLY products.
• The company's IPO in April 2025 raised approximately US$10.85 million in net proceeds.
• Significant increases in operating expenses, particularly professional fees related to business acquisitions and consultancy services, contributed to the widened net loss.
• The company continues to focus on its chronic wound care business, with MEDIFLY products forming the majority of its revenue, and is developing pipeline products including bullfrog collagen-based dressings and iodine-based antiseptics.
• Expansion into new geographic markets such as the Middle East and mainland China is planned for 2026 and 2027.
• The company is also venturing into medical waste recycling technology and IVF media production.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant increase in net loss and operating expenses, despite a slight revenue increase and successful IPO. The company's ability to achieve profitability remains uncertain.

Positives

• Revenue increased by 3.3% to S$49,894 (US$38,789) in 2025 compared to S$48,321 in 2024.
• The company successfully completed its IPO in April 2025, raising approximately US$10.85 million in net proceeds.
• MEDIFLY products continue to be the primary revenue driver, with patient numbers increasing from 78 in 2024 to 96 in 2025.
• Gross loss significantly decreased from S$3,024 in 2024 to S$645 (US$501) in 2025 due to increased revenue and stable cost of revenues.
• The company has a diversified business strategy, expanding into medical waste recycling and IVF media production.
• Strategic partnerships are in place for market expansion in Saudi Arabia, Hong Kong, and mainland China.

Negatives

• The company reported a net loss of S$4,673,447 (US$3,633,248) for the year ended December 31, 2025, an increase from S$1,560,535 in 2024.
• Operating expenses increased significantly by 194.1% to S$4,829,184 (US$3,754,322) in 2025, largely due to a substantial rise in other operating expenses, particularly professional fees.
• The company has an accumulated deficit of S$9,234,500 (US$7,179,118) as of December 31, 2025.
• The cost of revenues for MEDIFLY products remains high relative to revenue, with cost of revenues representing 101.3% of revenue in 2025.
• The company's maggot-based chronic wound care products lack patent protection, relying on trade secrets and know-how.
• Net cash used in operating activities increased significantly to S$9,133,948 (US$7,100,947) in 2025.

Risks

• The company has a history of losses and expects to continue incurring losses in the future, with no assurance of achieving or sustaining profitability.
• Failure to achieve widespread market acceptance for its products could materially and adversely affect the business.
• The regulatory approval and clearance processes for its products are lengthy, time-consuming, and unpredictable.
• The company relies on third-party agreements for the development and sale of certain pipeline products, and termination of these agreements could harm the business.
• Security breaches and other disruptions could compromise information and expose the company to liability.
• The company is dependent on a few major customers, with sales to its largest customer accounting for 28.3% of total revenue in 2025.
• The company is dependent on a few major suppliers, with purchases from its largest supplier accounting for 22.6% of total cost of sales in 2025.
• The company may not be able to maintain the listing of its Class A Ordinary Shares on the Nasdaq, which could limit investors' ability to trade them.
• The dual-class share structure may adversely affect the trading market for Class A Ordinary Shares.
• The company may need additional capital and may be unable to obtain it on acceptable terms.
• The company is subject to foreign exchange risks, although currently minimal.
• The company faces risks related to heightened inflation, recession, and financial market disruptions.
• The company is subject to credit risk from some customers, and failure to collect accounts receivable could adversely affect operations.
• The company is dependent on key management and skilled personnel, and the loss of their services could adversely affect the business.
• The company's maggot-based chronic wound care products are not currently protected by any pending patent application.

Future Outlook

The company plans to expand into new geographic markets including the Middle East and mainland China in 2026 and 2027. It also intends to explore the development of cosmeceutical products incorporating bullfrog collagen between 2026 and 2028. Additionally, the company plans to enter the medical waste recycling technology and IVF media production sectors.

Management Comments

• The company attributes its success and growth to the contributions and expertise of its directors and executive officers.
• The CEO, David Quek Yong Qi, plays a crucial role in management, fostering relationships with business partners and making strategic decisions.
• Dr. Ronald A. Sherman, Medical and Scientific Director, is instrumental in formulating business strategies and spearheading growth with his extensive industry and scientific knowledge.

Industry Context

StockSavvy.ai notes that Cuprina Holdings operates in the growing chronic wound care market, driven by an aging population and increasing prevalence of diseases like diabetes. The company's focus on bio-therapeutics and natural sources like bullfrog collagen positions it to capitalize on these trends, though it faces significant competition and regulatory hurdles.

Comparison to Industry Standards

• The company's MEDIFLY products are compared to conventional treatments for chronic wounds, with clinical studies suggesting faster debridement and shorter healing times.
• Aiodine's iodine-based solution demonstrated broad-spectrum antibacterial efficacy comparable to conventional povidone iodine in in vitro testing.
• Bullfrog collagen has shown superior biocompatibility, tensile strength, and thermal stability compared to mammalian and marine collagen in in vitro studies.
• The company's R&D workflow follows industry-standard phases from ideation to commercialization, including process investigation, prototyping, and regulatory approval.
• The company's quality management system is certified to ISO 13485:2016 standards, and it is working towards compliance with FDA's Quality Management System Regulation.

Corporate Governance

Legal Proceedings

• The company is not currently a party to, nor aware of, any legal or administrative proceedings that are likely to have a material adverse effect on its business, financial condition, cash-flow, or results of operations.

Related Party Transactions

• Advances for working capital were provided by Cuprina Holding Pte. Ltd., Jimmy Lee Peng Siew, David Quek Yong Qi, Bryan Teo Yingjie, Rachel Lee Lin, Dorea Quek En Qi, Teo Peng Kwang, and Ng Bee Poh.
• Amounts due from related parties include balances from Cuprina Pollination Pte. Ltd., Pestoniks Innovations Pte. Ltd., and Cuprina MENA Co., Ltd.
• Certain shareholders (De Guzman Caroline Francesca Lee Ling and iCapital Holdings (SG) Pte. Ltd.) ceased to be related parties as of December 31, 2025, after disposing of their shareholdings.
• The audit committee is tasked with reviewing and approving all related party transactions.

Stakeholder Impact

• Shareholders may experience dilution if additional Class B Ordinary Shares are issued.
• The concentrated control by directors, officers, and principal shareholders may limit the ability of Class A shareholders to influence corporate matters.
• The dual-class share structure might negatively impact the trading market for Class A Ordinary Shares.
• Investors may face difficulties in protecting their interests due to the company's incorporation under Cayman Islands law.
• The company's reliance on key personnel means their departure could adversely affect business operations.
• The company's ability to attract and retain skilled personnel is crucial for its success, and competition for such talent is intense.

Next Steps

• Expand sales and establish physical operations in the Middle East (GCC) and mainland China in 2026 and 2027.
• Explore the possibility of developing cosmeceutical product candidates incorporating bullfrog collagen between 2026 and 2028.
• Apply for operating licenses in Singapore to deploy medical waste recycling technology.
• Submit regulatory dossiers for IVF media products with HSA, aiming for commercial sales before Q4 2026.
• Commence safety and efficacy clinical trials for bullfrog collagen sponge dressings by the end of 2026.
• Submit 510(k) application to the FDA for bullfrog collagen sponge dressings by 2027.
• Register MEDIFLY products in Southeast Asian jurisdictions where partnerships have been established using the Common Submission Dossier Template (CSDT).

Key Dates

Recommendation

While the company has successfully completed its IPO and is expanding into new markets and product areas, the significant increase in net loss, high operating expenses, and continued reliance on external funding indicate ongoing financial challenges. The lack of patent protection for its core products and the long regulatory timelines for pipeline products add to the risk profile. Therefore, a 'hold' recommendation is appropriate, pending evidence of improved financial performance and successful commercialization of its pipeline.

Keywords

Cuprina Holdings, Form 20-F, Annual Report, Medical Devices, Chronic Wound Care, Maggot Debridement Therapy, MEDIFLY, Biotechnology, IPO, Nasdaq, Singapore, Financial Results